Core Viewpoint - Shanghai Yingli Pharmaceutical Co., Ltd. is facing operational challenges, including relocation due to disputes with the landlord, despite claiming that all business activities are proceeding normally [1][5][6]. Group 1: Company Operations - The company has confirmed that it is undergoing a relocation process primarily due to rental disputes, not operational issues [2][3]. - As of the latest reports, the company has around 30 employees remaining, and it is in the process of packing and moving equipment [3][4]. - Yingli Pharmaceutical has stated that all research, production, and operational activities are progressing as planned, with no abnormal circumstances affecting normal operations [5][6]. Group 2: Product Supply Issues - The core product, Linpulise (also known as "因他瑞"), has been experiencing supply shortages since the fourth quarter of 2025, affecting patients who rely on this medication [7][8]. - Patients have reported that the promised drug donation programs have not been fulfilled, leading to further distress among those dependent on Linpulise [8]. - The drug's price is set at 11,040 yuan per bottle, and its removal from the national medical insurance directory has significantly impacted its market accessibility [10]. Group 3: Legal and Financial Challenges - Yingli Pharmaceutical has been involved in over 30 lawsuits since 2025, primarily related to contract disputes with suppliers and service providers [11]. - The company has been ordered to pay approximately 2.25 million yuan due to a service contract dispute, which has also led to restrictions on its legal representative [11]. - The financial strain from these legal issues and operational challenges has raised concerns about the company's future viability and its reliance on a single product [10][11].

Core Viewpoint - The sudden discontinuation of the Alzheimer's drug, 甘露特钠胶囊 (brand name "九期一"), by Green Valley Pharmaceutical has led to a crisis for patients relying on this medication, with reports of counterfeit drugs flooding the market as a result of the supply shortage [1][2][4]. Group 1: Drug Supply Crisis - The discontinuation of 甘露特钠胶囊 began in early May 2025 and peaked in June, leaving many families of Alzheimer's patients in desperate search for alternatives [1][2]. - Green Valley Pharmaceutical stated that the production halt was due to the expiration of the drug's registration certificate, which is currently awaiting review [4]. Group 2: Counterfeit Drug Market - The shortage of the legitimate drug has led to a surge in counterfeit products being sold online, with misleading names such as "同仁堂甘露特钠胶囊" and "甘露药食同源浓缩丸" appearing on e-commerce platforms [6][11]. - Prices for the legitimate drug have skyrocketed, with reports of it being sold for as much as 5000 yuan per box, compared to the original monthly cost of approximately 296 yuan after insurance [4][2]. Group 3: Brand Misuse and Legal Issues - The issue of brand misuse is not new for 同仁堂, which previously reported 65 instances of its name being used fraudulently in March 2025 [11]. - The sale of counterfeit drugs has been identified as a criminal offense, with a notable case in May 2024 involving a live-streaming fraud scheme that targeted older adults, resulting in a financial loss of 30.89 million yuan [13].